Solubility enhancement techniques

International Journal of Pharmaceutical Sciences Review and Research

Volumn 5, Issue 1, 2010, Pages 41-51

  Vemula, Varun Raj ^a   Lagishetty, Venkateshwarlu ^a   Lingala, Srikanth ^b  

^a Vikas College of Pharmacy   (India)

^b ST PETER'S INSTITUTE OF PHARMACEUTICAL SCIENCES   (India)

Author keywords

Co solvent; Emulsions; pH; Solubility; Solubility enhancement

Indexed keywords

2 HYDROXYPROPYL BETA CYCLODEXTRIN; ALCOHOL; ALPHA CYCLODEXTRIN; BETA CYCLODEXTRIN; CARBAMAZEPINE; CYCLOSPORIN A; DIETHYLTOLUAMIDE; DIGOXIN; DIMETHYL SULFOXIDE; EXCIPIENT; GAMMA CYCLODEXTRIN; GLYCEROL; GRISEOFULVIN; MACROGOL; MACROGOL 4000; MACROGOL 8000; NIMODIPINE; PHENYTOIN; PROPYLENE GLYCOL; RAPAMYCIN; SOLVENT; SORBITAN OLEATE; TIPRANAVIR;

ACIDITY; ALKALINITY; AQUEOUS SOLUTION; CHEMICAL MODIFICATION; COMPLEX FORMATION; DISPERSION; DISSOLUTION; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG FORMULATION; DRUG MEGADOSE; DRUG RESPONSE; DRUG SOLUBILITY; LIQUID; MICELLIZATION; ORAL DRUG ADMINISTRATION; PH; REVIEW; SOLID; SOLUBILIZATION;

EID: 79952016122     PISSN: None     EISSN: 0976044X     Source Type: Journal    
DOI: None     Document Type: Review

References (100)

1. Bittner B, Mountfield R.J. Formulations and related activities for the oral administration of poorly water soluble compounds in early discovery animal studies. Pharm. Ind. 2002; 64: 800-807
2. Bittner B, Mountfield R.J. Intravenous administration of poorly soluble new drug entities in early drug discovery: the potential impact of formulation on pharmacokinetic parameters. Current opinion in drug discovery & development. 2002; 5: 59-71.
3. Meyer, M, C. "Bioavailability of drugs and bioequivalence In: Encyclopedia of Pharmaceutical Technology" New York. Marcel Dekker Inc.; 1998; 2, 33-58.
4. Shargil, L, & Yu, "Applied Biopharmaceuitcs" Appleton-Century Crofts, Norwalk, C.T, 1985; 2, 193-203.
5. Martin, A, "Physical pharmacy, " Lippincott Williams & Wilkins, A. Walters Kluwer Co, Philadelphia, 2003; 5, 410-418.
6. Carstensen, J, T, "Pharmaceutical Preformulation" Teelinomoc Publishing Co. Inc, 1998; 14-47.
7. Brahmankar D.M. et al, Bio pharmaceutics and Pharmacokinetics 2009; 349-357.
8. Martin, A, Bustamanate, P, and Chun, A, H, C, "Physical Pharmacy" B.I. Wavely Pvt. Ltd, New Delhi, 1994; 4, 223.
9. Osol, A, (Eds.) in: "Remington's Pharmaceutical sciences" Mack Publishing Company, Eastern Pennsylvania, 1990; 18, 203.
10. Neuberg, C, Hydrotrophy, Biochem J. Pharm, 1989; 75(7), 577.
11. st ed. Lippincott, Williams & Wilkins, 2005; 867-868.
12. Fiese E.F, Hagen T.A. Preformulation. In: Lachman L, Liberman H.A, Kanig J.L, editors. The theory and practice of industrial pharmacy. 3rd ed. Bombay: Varghees Publication House, 1990; 171-196.
13. Allen L.V, Popovich, N.G, Ansel H.C., Ansel's Pharmaceutical Dosage Forms and Drug Delivery Systems, Lippincott, Williams & Wilkins 2005; 100-101.
14. Venkatesh S, Y, Rao V, Anderson B. D, Intrinsic solubility estimation and pH-solubility behavior of cosalane (NSC 658586), an extremely hydrophobic diproticacid, Pharmaceutical Research, 1996; 13(10), 1453-1459.
15. Graham H, McMorland M, Joanne D, Wayne K, Peggy L.E, James E.A, James H.K.K, David R.G, Kerri R. Effect of pH-adjustment of bupivacaine on onset and duration of epidural analgesia in parturients, 1986; 33(5), 537-541.
16. Jain A, Ran Y, Yalkowsky S.H, Effect of pH-Sodium Lauryl Sulfate combination on solubilization of PG-300995 (an Anti-HIV Agent), AAPS PharmSciTech.2004; 5(3), 45-48.
17. Strickley R.G, Solubilizing excipients in oral and injectable formulations. Pharmaceutical Research, 2004; 21, 201-230.
18. Millard JW, Alvarez-Nunez FA, Yalkowsky SH., Solubilization by cosolvents. Establishing useful constants for the log-linear model. International Journal of pharmacy and Pharmaceutical sciences, 2002; 245, 153-166.
19. Strickley R.G, Parenteral formulations of small molecule therapeutics marketed in the United States (1999)-Part II. Journal of Parenteral Science and Technology, 2000; 54, 69-96.
20. Zhao L, Li P, Yalkowsky SH. Solubilization of fluasterone, Journal of Pharmaceutical Science, 1999; 88, 967-969.
21. Yalkowsky S. H, Joseph T. Rubino, Solubilization by cosolvents, Organic solutes in propylene glycol-water mixtures, Journal of Pharmaceutical Sciences, 1985; 74, 416-421.
22. Pan L, Tsutsui K, Takahashi L. Comparison of chromatographic and spectroscopic methods used to rank compounds for aqueous solubility. Journal of Pharmaceutical Sciences 2001; 90: 521-529.
23. Nema S, Washkuhn R.J, Brendel R.J. Excipients and their use in injectable products, Journal of Parenteral Science and Technology, 1997; 51, 166-171.
24. Rubino J.T, Yalkowsky S.H, Co-solvency and deviations from log-linear solubilization. Pharmaceutical Research, 1987; 4, 231-236.
25. Krishna G, Chen K.J, Lin C.C, Nomeir A.A, Permeability of lipophilic compounds in drug discovery using in-vitro human absorption model Caco-2. International Journal of pharmacy and Pharmaceutical sciences, 2001; 222, 77-89.
26. Seethala R, Fernandes, P.B, Handbook of Drug Screening, New York, Marcel Dekker, Inc, 2001; 597-601.
27. Seedher N, Bhatia S, Solubility enhancement of Cox-2 inhibitors using various solvent systems. AAPS PharmSciTech, 2003; 4, 33.
28. Chaumeil J.C. Micronisation, a method of improving the bioavailability of poorly soluble drugs, Methods and Findings in Experimental and Clinical Pharmacology, European Journal of Pharmaceutical Sciences, 2000; 10, 17-28
29. Muller R.H, Peters K, Becker R, Kruss B. Nanosuspension for IV administration of poorly soluble drugs-stability during sterilization and long term storage, 22nd International symposium, Control Release Bioact. Mater, Seattle, 1995; 22, 574-575.
30. Jayne Lawrence M, Rees G.D, Microemulsion-based media as novel drug delivery systems, Advanced Drug Delivery Reviews, 2000; 45(1), 89-121.
31. Danielsson I, Lindman B, The definition of microemulsion, Colloids Surfaces, 1981; 3, 391-392.
32. Holm R, Porter CJH, Edward GA, Mullertz, A, Kristensen HG, Charman WN, Examination of oral absorption and lymphatic transport of halofantrine in a triple cannulated canine model after administration in self-microemulsifying drug delivery systems (SMEDDS) containing structured triglycerides. European Journal of Pharmaceutical Sciences 2003; 20, 91-97.
33. Pouton CW. Lipid formulation for oral administration of drugs, non-emulsifying, selfemulsifying drug delivery systems. European Journal of Pharmaceutical Sciences 2000; 11, S93-S98.
34. Pouton CW. Formulation of self-microemulsifying delivery system. Advance Drug Delivery Reviews, 1997; 25, 47-58.
35. Ogino K, Abe M. Microemulsion formation with some typical surfactants, Surface and Colloid Science, Matijevic E, New York: Plenum Press, 1993, 85-95.
36. Lieberman H.A, Rieger M.M, Banker G.S. Pharmaceutical dosage forms, Disperse systems. New York, Marcel Dekker, Inc, 1998. 149-181.
37. Paul B.K, Moulik S.P. Microemulsions, an overview, Journal of Dispersion Science and Technology 1997; 18(4), 301-304.
38. Attwood D. Microemulsions. In Colloidal Drug Delivery Systems, Kreuter H. (ed.) New York, Marcel Decker Inc, 1994; 31-40.
39. Tenjarla S.N. Microemulsions: an overview and pharmaceutical applications. Therapeutic Drug Carrier Systems. 1999; 16, 461-521.
40. Kalaiarasi K, Shah D.O. Microemulsions: evolving technologies for cosmetic application, Journal of the Society of Cosmetic Chemistry, 1983; 34, 335-339.
41. Gershanik T, Benita S. positively charged self emulsifying oil formulation for improving oral bioavailability of progesterone, journal of Pharmaceutical Development and Technology, 1996; 1(2), 147-157.
42. Shah N.H, Carvajal M.T, Patel C.I, Infeld M.H, Malick A.W. Self-emulsifying drug delivery systems (SEDDS) with poly-glycolyzed glycerides for improving in vitro dissolution and oral absorption of lipophilic drugs. International Journal of pharmacy and Pharmaceutical sciences, 1994; 106, 15-23.
43. Gershkovich P, Hoffman A. Uptake of lipophilic drugs by plasma derived isolated chylomicrons and linear correlation with intestinal lymphatic bioavailability, European Journal of Pharmaceutical Sciences 2005; 26(5), 394-404.
44. Mueller E.A, Kovarik J.M, Van Bree J.B, Tetzloff W, Grevel J, Kutz K, Improved dose linearity of cyclosporine pharmacokinetics from a microemulsion Formulation. Pharmaceutical Research 1994; 11(2), 301-304.
45. Torchilin, V.P. Structure and design of polymeric surfactant based drug delivery system, Journal of Control Release, 2001; 73, 137-172.
46. Jones M.C, Leroux, J.C. Polymeric micelles-a new generation of colloidal drug carriers. European Journal of Pharmaceutics and Biopharmaceutics, 1999; 48, 101-111.
47. th edition, Baltimore, Willaims and Wilkins, 1993; 396-398.
48. Dutt G.B., Rotational diffusion of hydrophobic probes in Brij-35 micelles, Effect of temperature on miceller internal environment, Journal of Physical Chemistry B, 2003; 107: 10546-10551.
49. Shirley S, Sonia V.P, Eneida P, Surface active drugs self-association and interaction with membranes and surfactants and Physicochemical and biological aspects, International Journal of Biochemistry, Biophysics and Molecular Biology, 2000; 1508, 210-234.
50. Carlota O.R, Adalberto P.J, Leoberto C.T. Micellar solubilization of drugs. Journal of Pharmacy and Pharmaceutical Sciences, 2005; 8(2), 147-163.
51. Yua B. G, Okanob T, Kataokac K., Kwona G. Polymeric micelles for drug delivery, solubilization and haemolytic activity of Amphotericin B. Journal of Control Release, 1998; 53, 131-136.
52. K.G.H. Desai, A. R. Kulkarni, Aminabhavi TM, Solubility of rofecoxib in the presence of methanol, ethanol and sodium lauryl sulfate at (298.15, 303.15 and 308.15) K. Journal of Chem. Eng. Data 48:942-945 (2003).
53. C. Liu, K. G. H. Desai, and C. Liu. Solubility of valdecoxib in the presence of Ethanol and Sodium lauryl sulfate at (298.15, 303.15 and 308.15) K. Journal of Chem. Eng. Data, 2004; 49, 1847-1850.
54. K.G.H. Desai and H. J. Park. Solubility studies of valdecoxib in the presence of carriers, co-solvents and surfactants. Drug Development Research, 2004; 62, 41-48.
55. C.H. Hsu, Z. Cui, R. J. Mumper and M. Jay, Micellar Solubilization of Some Poorly Soluble Antidiabetic Drugs, AAPS PharmSciTech, 2008; 9 (2), 939-943.
56. Loftsson T, Brewster M.E., Pharmaceutical applications of cyclodextrins and Drug solubilization and stabilization, Journal of pharmaceutical sciences, 1996; 85, 1017-25.
57. Szente, L, Magisztrak, H, Szejtli, Formulation of insect controlling agents with beta-cyclodextrins, Journal of Pesticide Science, 1990; 28, 7-16.
58. Scalia, S., Villani, S, Casolari, A. Transdermal drug delivery: penetration enhancement techniques, Journal of Pharmacy and Pharmacology, 1999; 51, 1367-74.
59. Scalia, S., Villani, S. Scatturin, A, Vandelli, M.A, Forni, F. Complexation of sunscreen agent, butylmethoxy dibenzoyl methane, with hydroxyl propyl-β-cyclodextrin, International Journal of Pharmaceutics, 1998; 175, 205-213.
60. G S Tirucherai, A K Mitra, Effect of hydroxypropyl beta cyclodextrin complexation on aqueous solubility, stability, and corneal permeation of acyl ester prodrugs of ganciclovier. AAPS PharmSciTech, 2003; 4, E45.
61. N Bandi W Wei C B Roberts, L P Kotra, U B Kmpella. Preparation of budesonide and Indomethacin-hydroxipropyl β-cyclodextrin (HPBCD) complexes using a single-step, organic solvent free supercritical fluid process. European Journal of Pharmaceutical Sciences 2004: 24, 159-168.
62. Cao FT, Guo J, Ping Q. The Physicochemical Characteristics of Freeze-Dried Scutellarin-Cyclodextrin Tetracomponent Complexes. Drug Dev. Ind. Pharm, 2005; 31, 747-56
63. Deshmukh SS, Potnis VV, Shelar DB, Mahaparale PR. Studies on Inclusion Complexes of Ziprasidone Hydrochloride with beta-cyclodextrin and Hydroxypropyl beta-cyclodextrin. Indian Drugs, 2007; 44, 677-682.
64. Wen X, Tan F, Jing Z, Iiu Z. Prepration and study of the 1:2 Inclusion Complex of Carvedilol with β-Cyclodextrin, Simeoni, Journal of Pharmaceutical and Biomedical Analysis, 2004; 34, 517-523.
65. Loftsson, T.; Masson, M. Cyclodextrins in topical drug formulations: theory and practice, International Journal of Pharmaceutics, 2001; 225, 15-30.
66. Bentley, M.V., Vianna, R.F.; Wilson, S, Collett, J.H. Characterization of the influence of some cyclodextrins on the stratum corneum from the hairless mouse, Journal of Pharmacy and Pharmacology, 1997; 49, 397-402.
67. Sato, K., Sugibayashi, K., Morimoto, Y. Species differences in percutaneous absorption of nicorandil, Journal of Pharmaceutical Sciences, 1991; 80, 104-7.
68. Shaker, D.S., Ghanem, A.H., Li, S.K., Warner, K.S., Hashem, F.M., Higuchi, W.I. Mechanistic studies of the effect of hydroxypropyl-beta-cyclodextrin on in vitro transdermal permeation of corticosterone through hairless mouse skin, International journal of Pharmaceutics, 2003; 253, 1-11.
69. Loftsson T., Brewster M.E. Pharmaceutical applications of cyclodextrins: drug solubilization and stabilization. Journal of Pharmaceutical Sciences, 1996; 85:1017-1025.
70. Loftsson T, Brewter ME. "Cyclodextrin as Pharmaceutical Excipients". Pharma Manager, 1997; 5, 22-31.
71. Masson, Thorstein, Loftsoon, Gisli Masson, Einar Stefansson. Cyclodextrins as Permeation Enhancers; Some Theoretical Evaluations and invitro Testing. Journal of Control Release, 1997; 59, 107-18.
72. Prakash Rao B, Sarasija S, Narendra C. Recent Advances in Cyclodextrin Complexes; Mechanistic Analysis as Permeation Enhancers, Indian Journal of Pharmaceutical Education and Research, 2007; 41(2), 102-13.
73. Marttin E, Verhoef JC, Spies F, Vander Meulen J, Nagelkerke JF, Koerten HK, Merkus FWHM. The Effect of Methylated β-Cyclodextrins on the tight Junctions of the rat nasal Respiratory epithelium, Electron Microscopic and Confocal Laser Scanning and Microscopic Visualization Studies, Journal of Controlled Release 1994; 57, 205-13.
74. Gumbo T, Louie A, Deziel MR, Liu W, Parsons LM, Salfinger M, Drusano GL. Concentration-dependent Mycobacterium tuberculosis killing and prevention of resistance by rifampicin, Antimicrobial Agents, Chemotherapy, 2007; 51(11)3781-3788.
75. Louey MD, Garcia-Contreras L. Controlled release products for respiratory delivery. American Pharmacy Review, 2004; 7(4), 82-87.
76. Fores B, Ehrhardt C. Human respiratory epithelial cell culture for drug delivery applications, European Journal of Pharmaceutics and Biopharmaceutics, 2005; 60(2), 193-205.
77. Frederic T, Julien B, William C, Jean-Christophe O. Formulation of rifampicin cyclodextrin complexes for lung nebulization. Journal of Controlled Release, 2008; 129, 93-99.
78. Koester L.S., Bertuol J.B., Groch K.R., Xavier C.R., Moellerke R., Mayorga P., Dalla Costa T., Bassani V.L. Bioavailability of carbamazepine: betacyclodextrin complex in beagle dogs from hydroxypropyl methyl cellulose matrix tablets, European Journal of Pharmaceutical Sciences, 2004; 22(2-3), 201-207.
79. Thompson D.O. Cyclodextrins, enabling excipients: their present and future use in pharmaceuticals. Critcal Reviews in Therapeutical Drug Carrier System, 1997; 14, 1-104.
80. Rajewski R.A., Stella V.J. Pharmaceutical applications of cyclodextrins, in vivo drug delivery, Journal of Pharmaceutical Sciences, 1996; 85, 1142-1169.
81. Phillips E.M., Stella V.J. Rapid expansion from supercritical solutions, application to pharmaceutical processes. International Journal of Pharmaceutics, 1993; 94, 1-10.
82. Subramaniam B., Rajewski R.A., Snavely K. Pharmaceutical processing with supercritical carbon dioxide, Journal of Pharma Sciences, 1997; 86, 885-890.
83. 2. Journal of Supercritical Fluids, 2006; 78: 67-69.
84. Sunkara G., Kompella U.B. Drug delivery applications of supercritical fluid technology. Drug Delivery Technology 2002; 2, 44-50.
85. Wong D. H., Kim M. S., Lee S., Jeong S.P., Hwang S.J. Improved physicochemical characteristics of felodipine solid dispersion particles by supercritical anti-solvent precipitation process. International Journal of Pharmaceutics, 2005; 301, 199-208.
86. 2 for a novel melt dispersion micronization process. Journal of Molecular Liquids, 2007; 131-132.
87. Sekiguchi K., Obi N. Studies on absorption of eutectic mixture-I: A comparison of the behavior of eutectic mixture of sulfathiazole and that of ordinary sulfathiazole in man. Chem. Pharm. Bull. 1961; 9, 866-872.
88. Craig D.Q.M. The mechanisms of drug release from solid dispersions in water soluble polymers. International Journal of Pharmaceutics, 2002; 203, 131-144.
89. Hulsmann S., Backensfeld T., Keitel S., Bodmeier R. Melt extrusion-an alternative method for enhancing the dissolution rate of 17ß-estradiol hemihydrate, European Journal of Pharmaceutics and Biopharmaceutics, 2000; 49, 237-242.
90. Hirasawa N., Ishise S., Miyata H., Danjo K. Application of nilvadipine solid dispersion to tablet formulation and manufacturing using cross povidone and methylcellulose as dispersion carriers. Chem. Pharm. Bull, 2004; 52: 244-247.
91. Khoo S.M., Porter C.J.H., Charman W.N. The formulation of halofantrine as either nonsolubilising PEG 6000 or solubilising lipid based solid dispersions: physical stability and absolute bioavailability assessment. International Journal of Pharmaceutics, 2000; 205, 65-78.
92. Horisawa E., Danjo K., Haruna M. Physical properties of solid dispersion of a non-steroidal anti-inflammatory drug (M-5011) with eudragit E., Drug Development and Industrial Pharmacy, 2000; 26, 1271-1278.
93. Hirasawa N., Ishise S., Miyata H., Danjo K. Physicochemical characterization and drug release studies of nilvadipine solid dispersions using waterinsoluble polymer as a carrier. Drug Development and Industrial Pharmacy, 2003; 29(3), 339-344.
94. Deepika M., Jain A., Maheshwari R.K., Patidar V. Simultaneous spectrophotometric estimation of metronidazole and norfloxacin in combined tablet formulations using hydrotrophy. Asian Journal of Pharmaceutics, 2008; 1(4), 357-361.
95. Saleh A.M., Daabis, N.A. Study of the interaction of menadione with hydrotropic salts. Pharmazie, 1974; 29, 525-527.
96. Rasool A.A., Anwar A. H., Lewis W.D. Solubility enhancement of some water-insoluble drugs in the presence of nicotinamide and related compounds, Journal of Pharmaceutical Sciences, 2002; 80 (4), 387-393.
97. Badwana A.A., Khordaguib L.K., Saleh A.M., Khalil, S.A. The solubility of benzodiazepines in sodium salicylate solution and a proposed mechanism for hydrotropic solubilization. International journal of Pharmaceutics, 1982; 13(1), 67-74.
98. Balasubramanian, D. and Friberg, S. E., In Surface and Colloid Science (ed. Matijevic, E.), Plenum Press, New York, 1993, 15, 197-220.
99. Roy, B. K. and Moulik, S. P., Colloids Surface. A Physicochemical Engineering Aspects, 2002; 203, 155-166.
100. Patil S.V., Sahoo S. K., Pharmaceutical overview of spherical crystallization, Der Pharmacia Lettre, 2010; 2(1), 421-426.